New cancer drug enters first human safety trial
NCT ID NCT05781048
Summary
This is an early-stage study to test the safety and find the right dose of a new drug called HRS-6209 for people with advanced solid tumors. It will involve 56 patients whose cancer has progressed despite standard treatments. The main goals are to see how much of the drug the body can handle, identify any side effects, and get a first look at whether it might help shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center-
Shanghai, Shanghai Municipality, 201321, China
Conditions
Explore the condition pages connected to this study.